Is BioLife Solutions, Inc. overvalued or undervalued?

As of 28 February 2022, the valuation grade for BioLife Solutions, Inc. moved from fair to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 3.20 and an EV to Capital Employed ratio of 3.78, which suggest that the market is pricing the company at a premium despite its losses. Additionally, the negative EV to EBIT and EV to EBITDA ratios of -137.15 and -1053.88 respectively highlight significant operational challenges.
In comparison to peers, BioLife Solutions has a P/E ratio of -62.83, while Artivion, Inc. shows a much larger negative P/E of -268.22, and Embecta Corp. stands out with a positive P/E of 6.42, indicating that BioLife is struggling more than its peers. The company's stock has underperformed against the S&P 500 over multiple periods, notably with a 3-year return of 13.67% compared to the S&P 500's 70.41%, reinforcing the notion that it is overvalued in the current market context.